Yoshikatsu Kanai - Nanotechnology

Author Information

Yoshikatsu Kanai is a distinguished researcher affiliated with the Department of Bio-system Pharmacology at the Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. His research focuses on the role of amino acid transporters in cancer biology, particularly in relation to the L-type amino acid transporter 1 (LAT1) and its involvement in tumor growth, angiogenesis, and immune response.

Research Contributions

Yoshikatsu Kanai has made significant contributions to the understanding of amino acid transporters, particularly LAT1 (SLC7A5), and their roles in cancer biology. His research has explored the association of LAT1 with the immune system and prognosis in invasive breast cancer, the contribution of LAT1 to amino acid uptake in cancer cells, and the pharmacology of LAT1 as a target for drug discovery. His work has also delved into the upregulation of LAT1 in tumor-associated vascular endothelial cells, the functional analysis of LAT3 in prostate cancer, and the expression of LAT1 and 4F2hc in gastroenteropancreatic neuroendocrine neoplasms. These studies have provided valuable insights into the molecular mechanisms underlying cancer progression and potential therapeutic targets.

Aliases

Yoshikatsu Kanai is also known by the aliases Y Kanai and Y. Kanai.

Publication and Citation Metrics

Metric	Value
Citation Count	33,031
h-index	88
Paper Count	426

Publications:

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer

DOI: 10.1038/s41598-022-06615-8

Year: 2022

Contribution of LAT1 to amino acid uptake in cancer cells and suppression of cellular protein synthesis by LAT1 inhibitor

DOI: 10.1254/jpssuppl.95.0_1-ss-50

Year: 2022

Pharmacology of amino acid transporter LAT1 (SLC7A5): Roles in pathogenesis and the drug discovery targeting LAT1

DOI: 10.1254/jpssuppl.95.0_3-sl09

Year: 2022

Amino acid transporter LAT1 is upregulated in tumor-associated vascular endothelial cells and plays essential roles in tumor angiogenesis by promoting proliferation and regulating VEGF-A-dependent pro-angiogenic mTORC1 activation.

DOI: 10.1254/JPSSUPPL.94.0_3-O-F5-3

Year: 2021

Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor

DOI: 10.1111/cas.14991

Year: 2021

Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms

DOI: 10.21873/invivo.12520

Year: 2021

Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics.

DOI: 10.1016/j.pharmthera.2021.107964

Year: 2021

The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2

DOI: 10.1038/s41598-021-90748-9

Year: 2021

Structural insights into human excitatory amino acid transporter EAAT2

DOI: 10.1101/2021.11.03.465409

Year: 2021

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer

DOI: 10.21203/RS.3.RS-238356/V1

Year: 2021

What are the Challenges in Controlling Electron Occupancy?

Why Are Crystal Facets Important?

How Do Plasmonic Tweezers Work?

How Do These Software Tools Work?

What are Nano Generators?

How do Bioreceptors Work?

Why is the LCAO Model Important in Nanotechnology?

What is a Research Visa?

How Does SNSF Support Education?

Why are Nanoscale Metals Important?

Partnered Content Networks

Relevant Topics